Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 7, Issue 3, 2008, Pages 238-243

  Zebouh, Mohamed ^a   Thomas, Caroline ^a   Honderlick, Patrick ^b   Lemee, Ludovic ^c   Segonds, Christine ^d   Wallet, Frédéric ^a   Husson, Marie Odile ^a  

^a EA 3925   (France)

^b FOCH HOSPITAL   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d CHU PURPAN   (France)

Author keywords

Cystic fibrosis; E test; Overall MIC

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; TICARCILLIN; TOBRAMYCIN;

ACCURACY; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; GRAM NEGATIVE BACTERIUM; HUMAN; INOCULATION; INTERMETHOD COMPARISON; LUNG INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; SENSITIVITY ANALYSIS; SPUTUM ANALYSIS; TEST STRIP;

ADOLESCENT; ADULT; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SPUTUM;

EID: 43249105361     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2007.10.002     Document Type: Article

References (11)

1. Gibson R.L., Burns J.L., and Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168 (2003) 918-951
2. Rajan S., and Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 17 (2002) 47-56
3. Steinkamp G., Wiedemann B., Rietschel E., Krahl A., Gielen J., and Barmeier H. Emerging Bacteria Study Group. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 4 (2005) 41-48
4. Clinical and laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement. 2006; M1000-S16. wayne, PA: CLSI.
5. Van Dalfsen J.M., Stapp J.R., Phelps C., Stewart P., and Burns J.L. Comparison of two culture methods for detection of tobramycin-resistant Gram negative organisms in the sputum of patients with cystic fibrosis. J Clin Microbiol 40 (2002) 26-30
6. Ugolotti E., Belli M.L., and Fenu M.L. Evaluation of a new selective medium for recovery B. cepacia complex, S. maltophilia, A. xylosoxidans and other tobramycin-resistant organisms in the airways specimens of cystic fibrosis patients. J Cyst Fibros 1 (2002) P192
7. Dunne Jr. W.M., and Chusid M.J. Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis. Diagn Microbiol Infect Dis 6 (1987) 165-170
8. Van Horn K.G. Mixed morphotype broth microdilution susceptibility testing of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol 31 (1993) 458-459
9. Bolmstrom A., Arvidson S., Ericsson M., and Karlsson A. A novel technique for direct quantification of antimicrobial susceptibility of microorganisms. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy (1988) Los Angeles, USA: Marie-odile Husson (Abstract 1209)
10. G. Manno, E. Ugolotti, M.L. Belli, M.L. Fenu, L. Romano, M. Cruciani, 2003. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2006; 22: 28-34.
11. Balke B., Hogardt M., Schmoldt S., Hoy L., Weissbrodt H., and Haussler S. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 25 (2006) 25-30